Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility
ECONOMY & POLICY

Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility

Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.

The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.

The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.

In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.

Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.

Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.

News source: The Hindu


Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.News source: The Hindu

Next Story
Infrastructure Urban

InsideFPV Delivers ₹10 Crore Kamikaze Drone Order Under MoD’s EPR Route

InsideFPV, a Surat-based drone technology manufacturer, has successfully executed a ₹10 crore defence contract to supply indigenous kamikaze drones under the Ministry of Defence’s Emergency Procurement Route (EPR). The company completed the delivery of hundreds of FPV kamikaze drone platforms within a rapid two-month timeframe, highlighting its ability to meet urgent military procurement timelines.The supply orders were fulfilled under the emergency procurement mechanism, which is aimed at fast-tracking acquisitions for immediate operational needs. InsideFPV’s quick execution reflects it..

Next Story
Infrastructure Energy

Vedanta Resources Secures Fitch Upgrade to ‘BB-’, Best Rating Since 2015

Vedanta Resources Limited (VRL), a global player in metals, oil & gas, critical minerals, power and technology, has received a credit rating upgrade from Fitch Ratings, marking its strongest bond rating in over a decade.Fitch has raised Vedanta Resources’ Long-Term Foreign-Currency Issuer Default Rating (IDR) to ‘BB-’ from ‘B+’, while maintaining a Stable Outlook. The agency also upgraded VRL’s senior unsecured rating, along with the ratings of US dollar-denominated bonds issued by Vedanta Resources Finance II Plc and guaranteed by VRL, to ‘BB-’.The upgrade represents Vedan..

Next Story
Real Estate

NAREDCO NextGen NCR Chapter Launched

The NAREDCO NextGen NCR Chapter was recently launched at Excelerate 2026 in Mumbai, marking a key step towards integrating emerging real estate leaders from the National Capital Region with the national platform. The initiative aims to promote sustainable and responsible urban development through collaboration and knowledge exchange.The event brought together young developers, entrepreneurs, and professionals from across NCR, including Noida, Gurugram, Ghaziabad, Faridabad, Bhiwadi, and Meerut. Discussions focused on urban development, finance, sustainability, innovation, and policy, emphasisi..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement